Growth hormone treatment of Prader-Willi syndrome has long-term, positive effects on body composition

Acta Paediatrica, International Journal of Paediatrics

Volumn 104, Issue 4, 2015, Pages 422-427

  Höybye, Charlotte ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Body composition; Growth hormone deficiency; Long term growth hormone treatment; Prader Willi Syndrome

Indexed keywords

GROWTH HORMONE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; SOMATOMEDIN C; TRIACYLGLYCEROL; HUMAN GROWTH HORMONE;

ADULT; ADULTHOOD; ARTICLE; BODY COMPOSITION; BODY HEIGHT; BODY MASS; CHILDHOOD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY FAILURE; LONG TERM CARE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; POSITIVE END EXPIRATORY PRESSURE; PRADER WILLI SYNDROME; PRIORITY JOURNAL; SLEEP DISORDERED BREATHING; TREATMENT DURATION; DRUG EFFECTS; MIDDLE AGED; PRADER-WILLI SYNDROME; TIME; YOUNG ADULT;

ADULT; BODY COMPOSITION; CROSS-SECTIONAL STUDIES; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; PRADER-WILLI SYNDROME; TIME FACTORS; YOUNG ADULT;

EID: 84983584980     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/apa.12898     Document Type: Article

References (23)

1. Burman P, Ritzen EM, Lindgren AC,. Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. Endocr Rev 2001; 22: 787-99.
2. Whittington JE, Holland AJ, Webb T, Butler J, Clarke D, Boer H,. Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. J Med Genet 2001; 38: 792-8.
3. Cassidy SB, Schawartz S, Miller JL, Driscoll DJ,. Prader-Willi syndrome. Genet Med 2012; 14: 10-26.
4. Hoybye C, Hilding A, Jacobsson H, Thoren M,. Metabolic profile and body composition in adults with Prader-Willi syndrome and severe obesity. J Clin Endocrinol Metab 2002; 87: 3590-7.
5. Goldstone AP, Thomas EL, Brynes AE, Bell JD, Frost G, Saeed N, et al. Visceral adipose tissue and metabolic complications of obesity are reduced in Prader-Willi syndrome female adults: evidence for novel influences on body fat distribution. J Clin Endocrinol Metab 2001; 86: 4330-8.
6. Sode-Carlsen R, Farholt S, Rabben KF, Bollerslev J, Schreiner T, Jurik AG, et al. Body Composition, endocrine and metabolic profiles in adults with Prader-Willi Syndrome. Growth Horm IGF Res 2010; 20: 179-84.
7. Eldar-Geva T, Hirsch HJ, Benarroch F, Rubinstein O, Gross-Tsur V,. Hypogonadism in females with Prader-Willi syndrome from infancy to adulthood: variable combinations of a primary gonadal defect and hypothalamic dysfunction. Eur J Endocrinol 2010; 162: 377-84.
8. Hirsch HJ, Eldar-Geva T, Benarroch F, Rubinstein O, Gross-Tsur V,. Primary testicular dysfunction is a major contributor to abnormal pubertal development in males with Prader-Willi syndrome. J Clin Endocrinol Metab 2009; 94: 2262-8.
9. Hauffa BP, Schlippe G, Roos M, Gillessen-Kaesbach G, Gasser T,. Spontaneous growth in German children and adolescents with genetically confirmed Prader-Willi syndrome. Acta Paediatr 2000; 89: 1302-11.
10. Deal CL, Tony M, Höybye C, Allen DB, Tauber M, Christiansen JS, et al. Growth Hormone Research Society Workshop Summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab 2013; 98: E1072-87.
11. Hoybye C, Frystyk J, Thoren M,. The growth hormone-insulin-like growth factor axis in adult patients with Prader Willi syndrome. Growth Horm IGF Res 2003; 13: 269-74.
12. Sanchez-Ortiga R, Klibanski A, Tritos NA,. Effects of recombinant human growth hormone therapy in adults with Prader-Willi syndrome: a meta-analysis. Clin Endocrinol (Oxf) 2011; 77: 86-93.
13. Hoybye C,. Five-years growth hormone (GH) treatment in adults with Prader-Willi syndrome. Acta Paediatr 2007; 96: 410-3.
14. Butler MG, Smith BK, Lee J, Gibson C, Schmoll C, Moore WV, et al. Effects of growth hormone treatment in adults with Prader-Willi syndrome. Growth Horm IGF Res 2013; 23: 81-7.
15. Oto Y, Tanaka Y, Abe Y, Obata K, Tsuuchiya T, Yoshino A, et al. Exacerbation of BMI after cessation of growth hormone therapy in patients with Prader-Willi syndrome. Am J Med Genet A 2014; 164: 671-5.
16. Tanaka Y, Abe Y, Oto Y, Itabashi H, Shiraishi M, Yoshino A, et al. Characterisation of fat distribution in Prader-Willi syndrome: relationships with adipocytokines and influence of growth hormone treatment. Am J Med Genet A 2013; 161: 27-33.
17. Sode-Carlsen R, Farholt S, Rabben KF, Bollerslev J, Schreiner T, Jurik AG, et al. One year of growth hormone treatment in adults with Prader-Willi syndrome improves body composition-results from a randomised, placebo-controlled study. J Clin Endocrinol Metab 2010; 95: 4943-50.
18. Sode-Carlsen R, Farholt S, Rabben KF, Bollerslev J, Schreiner T, Jurik AG, et al. Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome. Growth Horm IGF Res 2011; 21: 185-90.
19. Höybye C,. Endocrine and metabolic aspects of adult Prader- Willi syndrome with special emphasis on the effect of growth hormone treatment. Growth Horm IGF Res 2004; 14: 1-15.
20. Talebizadeh Z, Butler MG,. Insulin resistance and obesity-related factors in Prader-Willi syndrome: comparison with obese subjects. Clin Genet 2005; 67: 230-9.
21. Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 1998; 83: 382-95.
22. Lafortuna CL, Minocci A, Capodaglio P, Gondoni LA, Sartorio A, Vismara L, et al. Skeletal muscle characteristics and motor performance after 2-year growth hormone treatment in adults with Prader-Willi Syndrome. J Clin Endocrinol Metab 2014; 99: 1816-24.
23. Coppini LZ, Waitzberg DL, Campos AC,. Limitations and validation of bioelectrical impedance analysis in morbidly obese patients. Curr Opin Clin Nutr Metab Care 2005; 8: 329-32.